Drug intelligence / Profile preview

Yinbei

Development stage: Preclinical
Lead developer: Sichuan New Green Pharmaceutical Technology
Administration: Oral

Overview

Yinbei Granules is a Traditional Chinese Medicine (TCM) formulation composed of several herbal ingredients, including Honeysuckle, Fritillaria thunbergii, Forsythia suspensa, oyster, burdock, magnolia, mint, Atractylodes macrocephala, and Astragalus membranaceus. It is being investigated for the treatment of adenoidal hypertrophy in children, specifically those diagnosed with "Phlegm Accumulation Syndrome" according to TCM principles. The granules are provided by Sichuan New Green Pharmaceutical Company and are administered orally.

Brand names: Yinbei granules
Other names: Yinbei Granules

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL8 (C-X-C Motif Chemokine Ligand 8)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Yinbei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yinbei.

Explore the full profile